Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr
Revenue increased 11.4 per cent to Rs. 8,545 crore
Revenue increased 11.4 per cent to Rs. 8,545 crore
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
The company’s largest center for medical device applications, serving the entire Asian market
Subscribe To Our Newsletter & Stay Updated